# A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer

> **NCT01872416** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Guangzhou Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DEVICE:** Liposomal Doxorubicin Combined With ifosfamide

## Key facts

- **NCT ID:** NCT01872416
- **Lead sponsor:** The First Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-10
- **Primary completion:** 2014-05
- **Final completion:** 2015-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2013-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01872416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01872416, "A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01872416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*